-
Mashup Score: 0
Adverse events from disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis decline by as much as 25% after the drugs are established on the market, according to data published in Annals of the Rheumatic Diseases. “Currently, there are safety concerns regarding treatment with Janus kinase inhibitors for patients with RA that limit their clinical use,” Viktor
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 0
Adverse events from disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis decline by as much as 25% after the drugs are established on the market, according to data published in Annals of the Rheumatic Diseases. “Currently, there are safety concerns regarding treatment with Janus kinase inhibitors for patients with RA that limit their clinical use,” Viktor
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
💡 STUDY: Adverse events from b/tsDMARDs for the treatment of rheumatoid #arthritis decline by as much as 2️⃣5️⃣% once the drugs have been established on the market More on the study out of @karolinskainst 🔽 https://t.co/tvg4ujFROq
-
-
Mashup Score: 0
Adverse events from disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis decline by as much as 25% after the drugs are established on the market, according to data published in Annals of the Rheumatic Diseases. “Currently, there are safety concerns regarding treatment with Janus kinase inhibitors for patients with RA that limit their clinical use,” Viktor
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
💡 STUDY: Adverse events from b/tsDMARDs for the treatment of rheumatoid #arthritis decline by as much as 2️⃣5️⃣% once the drugs have been established on the market More on the study out of @karolinskainst 🔽 https://t.co/tvg4ujFROq
-
-
Mashup Score: 0Odds of DMARD-free remission in rheumatoid arthritis may depend on biological DMARD use - 1 month(s) ago
Although sustained remission free of disease-modifying antirheumatic drugs “does not seem attainable” for patients with rheumatoid arthritis requiring biological DMARDs, it is possible for those who do not require them, according to data. The finding calls into question a EULAR recommendation, based on potentially flawed studies, discouraging DMARD cessation due to flare risks, Judith
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
🔎A @eular_org recommendation on DMARDs for rheumatoid #arthritis patients "might suffer from ascertainment bias," underrating the potential for DMARD-free remission, researchers found More on the study published in @TheLancetRheum ⬇️ https://t.co/wcRCCAN7Ou
-
-
Mashup Score: 1Rosnilimab Demonstrates Historic Responses for Rheumatoid Arthritis - 2 month(s) ago
The Phase 2b RENOIR trial met its primary endpoint and key secondary endpoints in patients with RA in new 12-week data.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
Rosnilimab has demonstrated historic ACR and CDAI LDA responses in patients with rheumatoid #arthritis in new findings from a phase 2b trial. Read more: https://t.co/GQBP9QiQHj
-
-
Mashup Score: 0Physicians may overlook ‘deep sense of vulnerability’ in patients with psoriatic arthritis - 2 month(s) ago
Uncertainty about future care and life impacts were among the top concerns for patients with psoriatic arthritis, but not for physicians, who highly prioritized individual symptoms, according to data published in ACR Open Rheumatology. The finding emerged from a study aiming “to better understand ‘what matters’ to patients with psoriatic arthritis” and determine whether
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
🔍 STUDY: Uncertainty about future care & life impacts were top concerns for psoriatic #arthritis patients ...but not for physicians, who highly prioritized individual symptoms 👨⚕️ We talked with study author Dr. Philip Mease @ProvSwedish 👇 https://t.co/mua83UscER
-
-
Mashup Score: 4TNF inhibitors do not increase adverse event risk in rheumatoid arthritis-associated ILD - 2 month(s) ago
Treatment with TNF inhibitors yielded no differences in outcomes vs. other antirheumatic therapies among U.S. veterans with rheumatoid arthritis-associated interstitial lung disease, according to data published in The Lancet Rheumatology. “There has been concern among providers about whether it is safe to use TNF inhibitors in patients with RA-ILD,” Bryant R. England, MD, PhD,
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
🫁 For rheumatoid #arthritis-associated ILD, TNF inhibitors led to respiratory hospitalization and mortality rates similar to other DMARDs TNF inhibitors ‘can remain a therapeutic option’ for RA-ILD, said Dr. Bryant England @UNMC_Rheum ⬇️ https://t.co/oVhjiMvAAE
-
-
Mashup Score: 4
While you wait for the groundhog to make his determination this weekend, take some time to buff up your knowledge of rheumatoid arthritis, a chronic autoimmune disease that affects about 1.5 million people in the United States. Sunday, Feb. 2, marks Rheumatoid Awareness Day, a time for spreading knowledge about this debilitating disease that too often lurks undetected. Early diagnosis and proper
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
☀️ ❄️ ❓ While you wait for the groundhog to make his determination this weekend, take some time to buff up your knowledge of rheumatoid #arthritis For Rheumatoid Awareness Day, Healio compiled all the RA news you might have missed ⬇️ https://t.co/25azkIdgcV
-
-
Mashup Score: 1
Delphi exercises revealed concordance between prioritized areas but also notable differences.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
New research has highlighted differences between patient and clinician perspectives in aspects of psoriatic #arthritis care. Read more: https://t.co/yLPtFdg4Pf
-
-
Mashup Score: 1Odds of DMARD-free remission in rheumatoid arthritis may depend on biological DMARD use - 3 month(s) ago
Although sustained remission free of disease-modifying antirheumatic drugs “does not seem attainable” for patients with rheumatoid arthritis requiring biological DMARDs, it is possible for those who do not require them, according to data. The finding calls into question a EULAR recommendation, based on potentially flawed studies, discouraging DMARD cessation due to flare risks, Judith
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
🔎A @eular_org recommendation on DMARDs for rheumatoid #arthritis patients "might suffer from ascertainment bias," underrating the potential for DMARD-free remission, researchers found More on the study published in @TheLancetRheum ⬇️ https://t.co/wcRCCAN7Ou
-
💡 STUDY: Adverse events from b/tsDMARDs for the treatment of rheumatoid #arthritis decline by as much as 2️⃣5️⃣% once the drugs have been established on the market More on the study out of @karolinskainst 🔽 https://t.co/tvg4ujFROq